ES2054740T3 - Pentadienamidas paf-antagonistas. - Google Patents

Pentadienamidas paf-antagonistas.

Info

Publication number
ES2054740T3
ES2054740T3 ES88110934T ES88110934T ES2054740T3 ES 2054740 T3 ES2054740 T3 ES 2054740T3 ES 88110934 T ES88110934 T ES 88110934T ES 88110934 T ES88110934 T ES 88110934T ES 2054740 T3 ES2054740 T3 ES 2054740T3
Authority
ES
Spain
Prior art keywords
diseases
paf
pentadienamides
antagonist
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88110934T
Other languages
English (en)
Inventor
Robert William Guthrie
Richard Wightman Kierstead
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2054740T3 publication Critical patent/ES2054740T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE LA FORMULA GENERAL (I) DONDE Y ES OXIGENO O UN ATOMO DE AZUFRE Y LOS DEMAS SUSTITUYENTES TIENEN EL SIGNIFICADO DADO EN LA INVENCION. LOS COMPUESTOS DE FORMULA (I) TIENEN ACCION COMO ANTAGONISTAS PAF Y PUEDEN SER APLICADOS EN ENFERMEDADES QUE SE CARACTERIZAN POR ELEVADO PAF O PARA EL TRATAMIENTO DE ALTERACIONES CIRCULATORIAS, ENFERMEDADES DE LOS PULMONES, ALTERACIONES INMUNOLOGICAS, INFLAMACIONES, ENFERMEDADES DE LA PIEL Y RECHAZOS A TRASPLANTES.
ES88110934T 1987-07-10 1988-07-08 Pentadienamidas paf-antagonistas. Expired - Lifetime ES2054740T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/072,389 US4788206A (en) 1987-07-10 1987-07-10 Pentadieneamides

Publications (1)

Publication Number Publication Date
ES2054740T3 true ES2054740T3 (es) 1994-08-16

Family

ID=22107243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88110934T Expired - Lifetime ES2054740T3 (es) 1987-07-10 1988-07-08 Pentadienamidas paf-antagonistas.

Country Status (21)

Country Link
US (1) US4788206A (es)
EP (1) EP0299379B1 (es)
JP (1) JPS6431766A (es)
KR (1) KR890001989A (es)
AT (1) ATE88466T1 (es)
AU (1) AU626526B2 (es)
CZ (1) CZ394991A3 (es)
DE (1) DE3880387D1 (es)
DK (1) DK378188A (es)
ES (1) ES2054740T3 (es)
FI (1) FI883290A7 (es)
HU (1) HU205902B (es)
IL (1) IL87017A0 (es)
MC (1) MC1954A1 (es)
MX (1) MX9203599A (es)
NO (1) NO883084L (es)
NZ (1) NZ225327A (es)
PH (1) PH24605A (es)
PT (1) PT87953B (es)
YU (1) YU46716B (es)
ZA (1) ZA884857B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0298466A3 (en) * 1987-07-10 1990-10-24 F. Hoffmann-La Roche Ag Substituted alkene carboxylic acid amides and derivatives
US5192766A (en) * 1989-04-28 1993-03-09 Sankyo Company, Limited N-acryloylpiperazine derivatives, their preparation and their use as PAF antagonists
US5369106A (en) * 1989-04-28 1994-11-29 Sankyo Company, Limited N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists
WO1997040011A1 (en) * 1996-04-23 1997-10-30 R. J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
KR100568997B1 (ko) * 1996-04-23 2006-12-15 타가셉트 인코포레이티드 중추신경계질환의예방및치료를위한약제학적조성물
AU2652397A (en) * 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
TR200001645T2 (tr) * 1997-12-11 2000-12-21 Janssen Pharmaceutica N.V. Retinoyik asit taklidi anilürler.
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
DE19828463A1 (de) * 1998-06-26 1999-12-30 Basf Ag 4,4-Diarylbutadiene als wasserlösliche photostabile UV-Filter für kosmetische und pharmazeutische Zubereitungen
CA2376061A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
BRPI0408005A (pt) * 2003-03-05 2006-02-14 Celgene Corp composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) * 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) * 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
TW200824687A (en) 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
MX2011001887A (es) * 2008-08-22 2011-04-04 Baxter Int Derivados de bencil carbonato polimericos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072649A (en) * 1963-01-08 S-tmalkoxycinnamamide derivatives
US4568687A (en) * 1983-02-28 1986-02-04 American Cyanamid Company N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
US4568685A (en) * 1984-02-29 1986-02-04 American Cyanamid Company N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides
US4542145A (en) * 1984-02-29 1985-09-17 American Cyanamid Company Substituted N-[(1H-1,2,4-triazol-1-yl)-alkyl]heteroarylcarboxamides
US4673684A (en) * 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPS6144869A (ja) * 1984-08-10 1986-03-04 Terumo Corp イミダゾ−ル誘導体およびこれを含有する血小板凝集抑制剤
JPS6144870A (ja) * 1984-08-10 1986-03-04 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
JPS6212757A (ja) * 1985-07-10 1987-01-21 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JPH06144869A (ja) * 1992-11-10 1994-05-24 Matsunami Glass Kogyo Kk バイオ担体用多孔質ガラス

Also Published As

Publication number Publication date
CZ394991A3 (en) 1993-01-13
PT87953B (pt) 1995-03-01
NO883084D0 (no) 1988-07-08
HU205902B (en) 1992-07-28
ZA884857B (en) 1989-04-26
NZ225327A (en) 1991-08-27
KR890001989A (ko) 1989-04-07
DK378188D0 (da) 1988-07-07
FI883290A0 (fi) 1988-07-08
IL87017A0 (en) 1988-12-30
MX9203599A (es) 1992-07-01
YU132488A (en) 1991-02-28
US4788206A (en) 1988-11-29
JPS6431766A (en) 1989-02-02
HUT48594A (en) 1989-06-28
PT87953A (pt) 1989-06-30
EP0299379A1 (de) 1989-01-18
DE3880387D1 (de) 1993-05-27
DK378188A (da) 1989-01-11
ATE88466T1 (de) 1993-05-15
FI883290A7 (fi) 1989-01-11
PH24605A (en) 1990-08-17
EP0299379B1 (de) 1993-04-21
MC1954A1 (fr) 1989-06-30
NO883084L (no) 1989-01-11
AU626526B2 (en) 1992-08-06
YU46716B (sh) 1994-04-05
AU1885188A (en) 1989-01-12

Similar Documents

Publication Publication Date Title
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
GR79463B (es)
BR8803709A (pt) Umectante para uma composicao de tratamento de pele e a respectiva composicao
ES2032456T3 (es) Procedimiento para preparar derivados de 1,2,5,6-tetrahidropiridin-3-carboxaldehido-oxima.
ES2061559T3 (es) Triazolinonas substituidas.
GB2096600B (en) Aroylimidazolones and analogues thereof
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
ES2063397T3 (es) Elaboracion de cauchos de poliuretano.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
ES507810A0 (es) Procedimiento para hidroformilar compuestos olefinicamente insaturados.
ATE9437T1 (de) Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen.
ES2043725T3 (es) Aminofenil-carbamatos substituidos.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE71078T1 (de) Glyzerinderivate.
IT1073249B (it) Composizioni per il trattamento di impermeabilizzazione di strutture naturali o artificiali
JPS51116092A (en) Footwear for automatically treating defecation of seriously limbs handicapped patient or the like
ES2068942T3 (es) Derivados del acido butenoico.
ES2059444T3 (es) Procedimiento para la obtencion de acroleinas alfa,beta-substituidas.
MX6274E (es) Procedimiento para la preparacion de composiciones parmaceuticas que contienen alcohilantes citostaticos destoxificados
ES2052622T3 (es) Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos.
JPS57185270A (en) Novel cyclic sulfenamides, manufacture and use as drug
ES2051778T3 (es) Procedimiento para preparar nuevas imidazo- y triazolotiadiazinas.
ES487818A0 (es) Procedimiento para la preparacion de nuevas sustancias analogas de prostaciclina
ES2053621T3 (es) Un procedimiento para preparar ciertas oxazolonas triciclicas cardiotonicas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 299379

Country of ref document: ES